Alexion - Innovative Drugs for Orphan Diseases = Driving Expectations and Valuations!

July 2012 | 5 pages | ID: AEBB1218CFEEN
MP Advisors

Abstracts

Alexion (ALXN) earnings and diversification strategy through acquisition of drugs targeting niche indications makes it a compelling long term investment proposition. 2Q12 earnings promised the growth of Soliris (L, PNH, aHUS) in various geographies and label expansion in other indications targeting rare and high unmet need. ALXN is investors’ choice as it meets expectations on earnings guidance, growth from pipeline and products carry low patent risk. ALXN’s experience in developing and marketing orphan drugs should increase its value beyond … For more detail, please read our report released on 1st Aug, 2012, titled, “Innovative Drugs for Orphan Diseases = Driving Expectations and Valuations!”